Literature DB >> 9065515

An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics.

D S Segal1, R Kuczenski.   

Abstract

Stimulant-induced psychosis is most frequently associated with a chronic, high-dose, multiple daily ("binge") exposure pattern of stimulant abuse. To simulate these conditions, rats were exposed to escalating doses of amphetamine (Escalating Dose phase, 1.0-8.0 mg/kg) before multiple daily injections of relatively high doses of the drug (Run phase, 8.0 mg/kg/2 hr x 4 injections). Behavior was monitored continuously during the course of these treatments as well as during subsequent amphetamine challenges at various times after discontinuation of drug treatment. With the Escalating Dose-Run pattern of administration, a unique behavioral profile emerged in which tolerance occurred to the amount of time spent engaged in continuous focused stereotypy simultaneous with a profound increase in ambulatory activity that appeared agitated and disorganized. Parallel in vivo microdialysis studies showed progressively declining extracellular dopamine and serotonin responses, both within and between successive runs, whereas the norepinephrine response remained relatively unaltered. We propose that this model more closely resembles clinical manifestations of amphetamine psychosis and that the alterations may reflect a shift in the relative activation of mesolimbic and nigro-striatal dopamine pathways.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9065515      PMCID: PMC6573483     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  70 in total

1.  A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis.

Authors:  L Ståhle; S Segersvärd; U Ungerstedt
Journal:  J Pharmacol Methods       Date:  1991-03

2.  Determination of brain interstitial concentrations by microdialysis.

Authors:  H Benveniste; A J Hansen; N S Ottosen
Journal:  J Neurochem       Date:  1989-06       Impact factor: 5.372

3.  Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates.

Authors:  D S Segal; R Kuczenski
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

4.  Serotonergic and cholinergic involvement in habituation of activity and spontaneous alternation of rats in a Y maze.

Authors:  A K Swonger; R H Rech
Journal:  J Comp Physiol Psychol       Date:  1972-12

5.  Continuous amphetamine intoxication: an animal model of the acute psychotic episode.

Authors:  G D Ellison; M S Eison
Journal:  Psychol Med       Date:  1983-11       Impact factor: 7.723

6.  A slow-release silicone pellet for chronic amphetamine administration.

Authors:  H S Huberman; M S Eison; K S Bryan; G Ellison
Journal:  Eur J Pharmacol       Date:  1977-10-01       Impact factor: 4.432

7.  Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size.

Authors:  E Castañeda; I Q Whishaw; T E Robinson
Journal:  J Neurosci       Date:  1990-06       Impact factor: 6.167

8.  Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics.

Authors:  R Kuczenski; D S Segal; M L Aizenstein
Journal:  J Neurosci       Date:  1991-09       Impact factor: 6.167

9.  Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine.

Authors:  G R Breese; B R Cooper; R A Mueller
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

10.  Haloperidol antagonism of cue-elicited cocaine craving.

Authors:  S P Berger; S Hall; J D Mickalian; M S Reid; C A Crawford; K Delucchi; K Carr; S Hall
Journal:  Lancet       Date:  1996-02-24       Impact factor: 79.321

View more
  32 in total

1.  Rat strain differences in responses of plasma prolactin and PRL mRNA expression after acute amphetamine treatment or restraint stress.

Authors:  V Klenerova; P Sida; S Hynie; J Jurcovicova
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

2.  The partial D2-like dopamine receptor agonist terguride acts as a functional antagonist in states of high and low dopaminergic tone: evidence from preweanling rats.

Authors:  Sanders A McDougall; Rita M Hernandez; Carmela M Reichel; Cristal M Farley
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

4.  Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.

Authors:  J Kitanaka; N Kitanaka; T Tatsuta; F S Hall; G R Uhl; K Tanaka; N Nishiyama; Y Morita; M Takemura
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

Review 5.  Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder.

Authors:  Marc A Mergy; Raajaram Gowrishankar; Gwynne L Davis; Tammy N Jessen; Jane Wright; Gregg D Stanwood; Maureen K Hahn; Randy D Blakely
Journal:  Neurochem Int       Date:  2013-12-08       Impact factor: 3.921

6.  α- and β-Adrenergic receptors differentially modulate the emission of spontaneous and amphetamine-induced 50-kHz ultrasonic vocalizations in adult rats.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

7.  Enhanced behavioral response to repeated-dose cocaine in adolescent rats.

Authors:  Joseph M Caster; Q David Walker; Cynthia M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

8.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

9.  Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice.

Authors:  Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Brain Res       Date:  2012-08-31       Impact factor: 3.332

10.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.